Lv41
660 积分 2024-04-24 加入
Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors
12天前
已完结
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply
27天前
已完结
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma
27天前
已完结
Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review
28天前
已完结
Malignancies after chimeric antigen receptor T-cell therapy
28天前
已完结
Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China
1个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
1个月前
已完结
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
1个月前
已完结
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
1个月前
已完结
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
1个月前
已完结
皖公网安备34019202002308
